PerkinElmer hits the check­book again, this time dol­ing out $260M for next-gen ther­a­py bioser­vices firm

When PerkinElmer iced a deal to pick up UK gene edit­ing firm Hori­zon Dis­cov­ery, it trum­pet­ed its big move in­to next-gen ther­a­peu­tics. Now, not con­tent to sit on its lau­rels, PerkinElmer is dip­ping in­to the war chest again, this time for a firm spe­cial­iz­ing in cut­ting-edge bioser­vices.

Life sci­ences ser­vices gi­ant PerkinElmer will shell out $260 mil­lion to ac­quire Lawrence, MA-based Nex­celom Bio­science, which of­fers clin­i­cal ser­vices for next-gen cell and gene ther­a­pies, im­muno-on­col­o­gy drugs and vac­cines, the com­pa­nies said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER